Compare RVSB & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | TNYA |
|---|---|---|
| Founded | 1923 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 153.2M |
| IPO Year | 1997 | 2021 |
| Metric | RVSB | TNYA |
|---|---|---|
| Price | $5.30 | $0.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $7.00 | $5.33 |
| AVG Volume (30 Days) | 52.3K | ★ 1.7M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $65.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.81 | $0.53 |
| 52 Week High | $6.22 | $2.35 |
| Indicator | RVSB | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 36.60 |
| Support Level | $5.23 | $0.66 |
| Resistance Level | $5.56 | $0.82 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 88.33 | 10.59 |
Riverview Bancorp Inc is the bank holding company. The Company's operations are managed along two operating segments, consisting of banking operations performed by the Bank and trust and investment services performed by the Trust Company. The Bank is engaged mainly in the business of attracting deposits from the general public and using such funds, together with other borrowings, to make various commercial business, commercial real estate, land, multi-family real estate, real estate construction and consumer loans. Additionally, the Trust Company offers trust and investment services. It has single operating segment.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.